H.C. Wainwright Reiterates Buy Rating on Greenwich LifeSciences (GLSI)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $50.00 price target on Greenwich LifeSciences (NASDAQ: GLSI).

The analyst commented: "Last week, Greenwich LifeSciences provided an update on its cash burn rate and financing strategy. At the end of December 2025, the company had $6M in cash. The company raised approximately $7M via its ATM facility during the first three weeks of January 2026, bringing the cash position to $12.5M as of January 23, 2026. Given the annual burn rate of $9.5M in 2025 and the modest increase in cash burn rate in 2026, management expects the current cash balance to exceed the company’s cash needs for all of 2026. Of note, continued use of the ATM may provide a bridge to non-dilutive funding, such as strategic/licensing partnerships or debt/royalty financing vehicles. We reiterate our Buy rating and $50 PT."

For an analyst ratings summary and ratings history on Greenwich LifeSciences click here. For more ratings news on Greenwich LifeSciences click here.

Shares of Greenwich LifeSciences closed at $27.01 yesterday.

You May Also Be Interested In

• Benchmark Downgrades Roblox Corp. (RBLX) to Sell, 'Ah Heck, Here We Go Again'
• Guardant Health (GH) PT Raised to $180 at Stifel
• Merit Medical Systems, Inc. (MMSI) PT Raised to $101 at Needham